TAK-960

• CAT Number: I000520
• CAS Number: 1137868-52-0
• Purity: ≥95%
• Target: PLK
• Solubility: DMSO: ≥ 35 mg/mL
• Storage: Store at -20°C
• IC50: 1.5 nM

TAK-960 (CAT: I000520) is a promising investigational drug that belongs to the class of polo-like kinase 1 (PLK1) inhibitors. It is designed to specifically target and inhibit the activity of PLK1, a protein involved in cell division and proliferation. TAK-960 has demonstrated potent inhibitory activity against PLK1, with an IC50 value of 1.5 nM. It has shown efficacy in various tumor cell lines, including those resistant to multidrug therapy. TAK-960 is being studied for its potential as a therapeutic agent in the treatment of cancer.

Reference

1:Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1). Nie Z, Feher V, Natala S, McBride C, Kiryanov A, Jones B, Lam B, Liu Y, Kaldor S, Stafford J, Hikami K, Uchiyama N, Kawamoto T, Hikichi Y, Matsumoto S, Amano N, Zhang L, Hosfield D, Skene R, Zou H, Cao X, Ichikawa T.Bioorg Med Chem Lett. 2013 Jun 15;23(12):3662-6. doi: 10.1016/j.bmcl.2013.02.083. Epub 2013 Feb 27. PMID: 23664874 2:TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Hikichi Y, Honda K, Hikami K, Miyashita H, Kaieda I, Murai S, Uchiyama N, Hasegawa M, Kawamoto T, Sato T, Ichikawa T, Cao S, Nie Z, Zhang L, Yang J, Kuida K, Kupperman E.Mol Cancer Ther. 2012 Mar;11(3):700-9. doi: 10.1158/1535-7163.MCT-11-0762. Epub 2011 Dec 21. PMID: 22188812 Free Article